Table 6.

Time to first ocular adverse event and comparisons among treatment groups.

Ocular event during follow up	Treatment	N Events/ N at risk	Cumulative % at 24 weeks (95% CI)	Treatment Comparison	Hazard ratio (95% CI)	P-value
≥ 10mmHg increase in IOP from baseline	Periocular	9 / 74	14 (5,22)	Intravitreal/ Periocular	1.92 (0.86,4.29)	0.11
	Intravitreal	18 / 81	26 (13,38)	Dexamethasone/ Periocular	2.85 (1.30,6.28)	0.009
	Dexamethasone	24 / 78	39 (20,53)	Dexamethasone/ Intravitreal	1.43 (0.72,2.81)	0.30
IOP ≥ 24 mm Hg	Periocular	13 / 74	20 (9,29)	Intravitreal/ Periocular	1.83 (0.91,3.65)	0.09
	Intravitreal	24 / 81	30 (17,40)	Dexamethasone/ Periocular	2.52 (1.29,4.91)	0.007
	Dexamethasone	29 / 78	41 (26,53)	Dexamethasone/ Intravitreal	1.32 (0.72,2.43)	0.37
IOP ≥ 30 mm Hg	Periocular	4 / 74	6 (0,12)	Intravitreal/ Periocular	1.07 (0.28,4.01)	0.92
	Intravitreal	5 / 81	6 (1,12)	Dexamethasone/ Periocular	0.71 (0.16,3.11)	0.65
	Dexamethasone	3 / 78	4 (0,8)	Dexamethasone/ Intravitreal	0.64 (0.16,2.59)	0.53
Hypotony (IOP < 6 mm Hg)	Periocular	1 / 71	12 (0,30)	Intravitreal/ Periocular	Not estimable
	Intravitreal	5 / 81	6 (1,12)	Dexamethasone/ Periocular	6.17 (0.97,39.38)	0.05
	Dexamethasone	5 / 77	12 (0,24)	Dexamethasone/ Intravitreal	1.08 (0.31,3.71)	0.90
Initiating IOP lowering medication	Periocular	14 / 58	32 (13,46)	Intravitreal/ Periocular	1.38 (0.68,2.80)	0.37
	Intravitreal	20 / 65	43 (22,59)	Dexamethasone/ Periocular	1.58 (0.76,3.29)	0.22
	Dexamethasone	20 / 60	34 (18,48)	Dexamethasone/ Intravitreal	1.12 (0.54,2.29)	0.76
VA decrease of 15 or more standard letters	Periocular	8 / 74	11 (4,18)	Intravitreal/ Periocular	0.33 (0.09,1.24)	0.10
	Intravitreal	3 / 81	10 (0,22)	Dexamethasone/ Periocular	0.46 (0.14,1.50)	0.20
	Dexamethasone	4 / 78	5 (0,10)	Dexamethasone/ Intravitreal	1.45 (0.34,6.26)	0.62

IC = confidence interval; IOP = intraocular pressure; VA = visual acuity; IOP = intraocular pressure.